The Sleep Apnea Device Market Valued at USD 6.2 billion in 2023, projected to grow from USD 6.6 billion in 2024 to USD 11.60 billion by 2032, exhibiting a CAGR of 7.10% during the forecast period (2024 - 2032). Growing public awareness, the aging population, the prevalence of the condition, and the need for better OSA diagnosis and treatment are a few of the major market drivers influencing the growth of the sleep apnea market.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
January 2024
Philips, a Dutch health technology company, inaugurates the latest tab and will not sell new devices to treat sleep apnea in the U.S. in the forthcoming years as it works to fulfill a clearance with the Food and Drug Administration (FDA) announced on January 15th. The agreement saw the remembrance of millions of breathing devices and ventilators utilized to treat sleep apnea in 2021 due to fears that foam used to lower noise from the gadgets could degrade and become toxic, containing potential cancer risks.
Philips said it had attained what is known as an approval declaration that spells out the developments its requirements to make at its Respironics plants in the U.S. Until the specifications are met, no new Respironics gadgets will be sold in the U.S., the company alleged. Philips shares were down 8.3% at 1405 GMT in Amsterdam after news of the deal, which ING specialist Marc Hesselink said was "very punitive".
Hesselink said in a note that they believe it will be very difficult for Philips to regain its U.S. Respironics market position. Citi analyst Mathieu Chevrier said that he had formerly supposed Philips would return to the U.S. market in July. Still, January 15th's announcement delays the timeline and is likely a positive for rival ResMed. Shares of ResMed ascended almost 2% in early U.S. trading. The decree is being confirmed and will be accepted by the related U.S. court for agreement.
It was not clear how long that would take. CEO Roy Jakobs failed to give information on the requirements that Philips will have to endure, but as a general sign said, it, on average, takes between five and seven years to submit approved decrees in the medical equipment industry.
In November 2023, FDA 510k Clearance was secured by Vivos Therapeutics for their CARE (Complete Airway Repositioning and/or Expansion) oral devices that are customized for adults with severe obstructive sleep apnea (OSA). The company’s leading DNA, mRNA, and mmRNA mouth appliances are included in the clearance.
For instance, Fisher & Paykel Healthcare Corporation Limited introduced the F&P Solo mask for Obstructive Sleep Apnea (OSA) treatment in New Zealand and Australia in October 2023. This AutoFit nasal and pillow mask simplifies setup process, hence enhancing user convenience. Such initiatives are projected to drive the growth of this segment.
In October 2023, ResMed entered into a distributorship agreement with Bittium Biosignals Ltd., a Bittium Corporation subsidiary, making ResMed its distributor of Bittium Respiro, a comprehensive Home Sleep Apnea Test and Analysis Solution. The complete solution comprises the measuring device called Bittium Respiro (and its accessories), as well as the software analysis tool known as Bittium Respiro Analyst and service platform. The non-exclusive agreement will encompass the United Kingdom (UK), Norway, Switzerland, plus the Republic of Ireland, Finland, Sweden.
In September 2023, ResMed entered into a strategic partnership with Nyxoah to create awareness about OSA among the German population, thereby increasing therapy penetration, which will spur the market growth during the forecast period.
In July 2023, Somnoware, which is a U.S leader in sleep and respiratory care Home Care software, was acquired by ResMed.
In June 2023, Inspire Medical Systems, located in the US, obtained an expanded FDA approval for its neurostimulation technology-based medical device – an alternative traditional CPAP machine for treating sleep apnea disorder. This extended approval is expected to enable delivering of this equipment to OSA patients suffering from serious conditions.
In June 2023, Fisher Paykel Company signed a product / technology integration agreement with VGM & Associate, which is a US-based hospital. It has been revealed that Fisher Paykel announced its plans to use the myAirvo line of products to support VGM members according to this agreement.
Obstructive sleep apnea (OSA), which affects 18 million Americans, is thought to affect 1 in 15 persons in the country, according to research from Sleep Science Resource, LLC. People's sedentary lifestyles have increased the prevalence of obesity, disturbed sleep patterns, high levels of stress, and cardiovascular disorders. For instance, multiple cross-sectional studies have suggested that severe sleep apnea is prevalent in 40% of the obese population and that 70% of OSA patients are obese, according to the article published by American Heart Association, Inc. Also, between 13.0% and 32.0% of the elderly population in Europe had sleep apnea, according to data released by the European Respiratory Society. A sizable patient pool needs to be treated or managed for the illness due to rising rates of obesity and other lifestyle disorders, as well as rising sleep apnea diagnosis rates in both industrialised and developing nations. This, together with an increase in sleep clinics and sleep technicians worldwide, is promoting market expansion. Additionally, there is a sizable population of unidentified patients, particularly in underdeveloped nations. Through various efforts like "sleep awareness week," numerous groups and governmental organisations are concentrating on raising the awareness and diagnostic rates among these people. Additionally, it is projected that this will fuel market expansion over the upcoming years. Thus, this factor is driving the market CAGR for sleep apnea device.
Figure 1: Prevalence of Osteroarthritis
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Furthermore, the development of novel alternatives for the treatment of sleep apnea has been greatly aided by the shift of patients towards technologically improved gadgets. For instance, due to patient discomfort with CPAP machines, the usage of oral devices such the mandibular advancement device (MAD) for OSA treatment has increased. Additionally, it is estimated that the compliance rate for CPAP devices among users has decreased by up to 50.0%, according to data published by NCBI based on various studies carried out in different countries. This has caused the market to introduce alternatives like oral appliances, which have proven to be efficient and provide comfort to patients during the treatment of the disorder.
Along with this, the non-invasive nature of the actometer and its lower price compared to conventional polysomnography equipment have made it extremely popular among sleep clinics (PSG). As a result, patients are increasingly turning to oral appliances and actometers for successful management of sleep apnea due to rising non-adherence for CPAP equipment and increased demand for affordable diagnostic gadgets. Thus, it is anticipated that this aspect will accelerate sleep apnea device market revenue globally.
The Market segments of Sleep Apnea Device, based on type, includes Diagnostic Devices and Therapeutic Devices. The therapeutic devices segment held the majority share in 2022 in the Sleep Apnea Device Market data due to an increase in the number of diagnosed individuals receiving treatment at sleep clinics, particularly in wealthy nations, which includes CPAP therapy. Around 95% of Americans with diagnoses receive therapy, and CPAP is the most popular form of treatment among these patients, according to KOL interviews.
August 2021: ResMed, a leader in digital health and the treatment of sleep apnea, unveiled AirSense 11, its next-generation Positive Airway Pressure (PAP) device. This device is intended to help hundreds of millions of people with sleep apnea around the world begin and maintain treatment for managing obstructive sleep apnea.
Figure 2: Sleep Apnea Device Market, by Type, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Sleep Apnea Device Market segmentation, based on application, includes Home Care Settings and Sleep Laboratories & Hospitals. The home care settings segment dominated the market growth for sleep apnea device in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. Players in the market are concentrating on producing novel, portable gadgets for patients receiving treatment for the ailment to use at home. The need for these devices in homecare and other settings is rising as a result of this and the growing desire for treating OSA at home, particularly in nations like the U.S., U.K., Germany, and Japan, among others.
By region, the study provides the market insights for sleep apnea device into North America, Europe, Asia-Pacific and Rest of the World. North America sleep apnea device market accounted for USD 2.5 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. The higher frequency of the illness and the advantageous reimbursement rules, which have been essential in the larger adoption of such devices in the region, are to blame for North America's supremacy. The American Academy of Sleep Medicine (AASM) estimates that in the United States, 2.0%-5.0% of women and 3.0%-7.0% of males suffer from sleep apnea.
Further, the major countries studied in the market report for sleep apnea device are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: Sleep Apnea Device Market Share by Region 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe sleep apnea device market accounts for the second-largest market share. This is attributable to growing awareness of sleep apnea, as well as an increase in the need for diagnostic testing, a favourable reimbursement environment, and expanding device penetration in this area. For instance, on September 15, 2022, ProSomnus, a pioneer in precise medical devices for the management of OSA, announced that the German public health insurance system officially covers the ProSomnus EVOTM Sleep and Snore Device. Further, the UK market of sleep apnea device held the largest market share, and the Germany market of sleep apnea device was the fastest growing market in the region.
Asia Pacific sleep apnea device Market is expected to grow at the fastest CAGR from 2024 to 2032 due to the rising prevalence of lifestyle disorders such chronic respiratory illnesses, cancer, hypertension, and diabetes, as well as the growing senior population. As per the OECD iLibrary article on Asia/Pacific 2020, approximately 227 million individuals are diagnosed with type 2 diabetes in the Asia Pacific. Moreover, China market of sleep apnea device held the largest market share, and the India market of sleep apnea device was the fastest growing market in the region.
Sleep Apnea Device Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the market of sleep apnea device grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the sleep apnea device industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the global sleep apnea device industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, sleep apnea device industry has provided medicine with some of the most significant benefits. The sleep apnea device market major player such as ResMed, LivaNova, Nihon Kohden, GE Healthcare, Natus Medica, Cadwell, Curative Medical and Koninklijke Philips.
The medical equipment business ResMed Inc. is situated in San Diego, California. For the treatment of sleep apnea (with CPAP machines and masks, for example), chronic obstructive pulmonary disease (COPD), and other respiratory disorders, it primarily offers cloud-connected medical devices. Hundreds of thousands of ventilators and bilevel devices were created by ResMed to assist in treating COVID-19 patients' respiratory difficulties. In November 2022, ResMed and the biological sciences division of Alphabet Verily announced the launch of Primasun, an all-inclusive tool to assist employers and healthcare professionals in identifying people at risk for complicated sleep problems.
A multinational provider of medical technology, GE HealthCare Technologies Inc., doing business as GE Healthcare, is based in Chicago, Illinois. As of 2017, it produces and distributes radiopharmaceuticals and diagnostic imaging agents for imaging modalities used in medical imaging procedures. In September 2022, to hasten the digital transformation of healthcare throughout Europe, the Middle East, and Africa, GE Healthcare and Wayra partnered with seven health tech start-ups.
Key Companies in the market of sleep apnea device includes
Sleep Apnea Device Industry Developments
February 2023: LivaNova PLC (UK) launched SenTiva DUO, an implantable pulse generator (IPG) with a dual-pin header to provide VNS Therapy for the treatment of drug-resistant epilepsy
October 2022: The launch of flexTAP, a premium lab-made oral appliance intended to treat individuals with snoring and mild to moderate obstructive sleep apnea, was announced by Airway Management, a maker of the most extensively studied custom oral appliances.
October 2021: For patients to receive a comprehensive whole-mouth treatment for OSA, Candid just established a strategic relationship with Vivos Therapeutics, a company that treats obstructive sleep apnea. Through this strategic alliance, adult patients will have access to orthodontic treatments from the same provider network as well as a diagnosis and treatment for OSA.
North America
Europe
Asia-Pacific
Rest of the World
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 6.2 billion |
| Market Size 2024 | USD 6.64 billion |
| Market Size 2032 | USD 11.6 billion |
| Compound Annual Growth Rate (CAGR) | 7.1% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018 - 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Product, Application, End User and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | ResMed, LivaNova, Nihon Kohden, GE Healthcare, Natus Medica, Cadwell, Curative Medical and Koninklijke Philips |
| Key Market Opportunities | Product development and launch |
| Key Market Dynamics | Technological advancements Product adaptation |
Frequently Asked Questions (FAQ) :
The Sleep Apnea Device Market size was valued at USD 6.2 Billion in 2023.
The Sleep Apnea Device Market is projected to grow at a CAGR of 7.1% during the forecast period, 2024-2032.
North America had the largest share in the global market for sleep apnea device.
The key players in the market for sleep apnea device are ResMed, LivaNova, Nihon Kohden, GE Healthcare, Natus Medica, Cadwell, Curative Medical and Koninklijke Philips.
The therapeutic devices dominated the sleep apnea device market in 2022.
The home care settings had the largest share in the Sleep Apnea Device Market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
